Welcome to our dedicated page for eXoZymes news (Ticker: EXOZ), a resource for investors and traders seeking the latest updates and insights on eXoZymes stock.
eXoZymes Inc. develops AI-enhanced enzymes and a cell-free biomanufacturing platform for producing high-value natural products from abundant feedstock. Company news centers on exozymes, enzyme cascades operating outside living cells, and the use of the platform in nutraceuticals, novel medicines, active pharmaceutical ingredients, biofuels, food flavors, cosmetics, and valuable chemicals.
Recurring updates cover N-trans-caffeoyltyramine, or NCT, NCTx commercialization activity, pilot-scale production and technology-transfer work, partner validation, strategic focus on pharmaceutical and nutraceutical markets, accelerator participation, investor presentations, and periodic operating results communications.
eXoZymes (NASDAQ: EXOZ) announced significant leadership changes in its board of directors. Mo Hayat has stepped down as Chairman and President to focus on new ventures at MDB Capital. Edgardo Rayo, who initially discovered the scientific co-founders at UCLA, joins the board representing MDB Capital. Christopher Marlett, current board member and CEO of MDB Capital, will become Chairman.
Michael Heltzen, CEO of eXoZymes, will now also serve as President. The transition follows the company's recent rebranding from Invizyne Technologies and ticker change to 'EXOZ' on February 12, 2025. eXoZymes specializes in AI-engineered enzymes that transform sustainable feedstock into essential chemicals, medicines, and biofuels.
eXoZymes (Nasdaq: EXOZ), a company specializing in AI-engineered enzymes for transforming sustainable feedstock into chemicals, medicines, and biofuels, announced that CEO Michael Heltzen and team members will ring the Nasdaq closing bell on February 19, 2025. This ceremony commemorates their successful IPO, which closed on November 14, 2024, with shares priced at $8 per share.
The bell ringing ceremony will be broadcast live at 3:50 p.m. Eastern Time from the Nasdaq MarketSite Tower in New York City. The company views this milestone as a marker of transition into what they call the 'exozymes era of biotechnology,' following the synthetic biology era.